|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1992-11-18
|
|
pubmed:abstractText |
Initial studies determined whether intraperitoneal (i.p.) injection of BALB/c mice with 0.1, 1.0, and 10 mg of adriamycin (a cardiotoxic anthracycline antibiotic) for times ranging between 1 and 9 weeks prior to i.p. injection of 10(5) PFU of coxsackievirus B3 (CVB3) would alter the severity of virus-induced myocarditis. Prior adriamycin exposure enhanced pathogenicity of a poorly pathogenic CVB3 variant (H310A1) but had no effect on myocarditis produced by the pathogenic variant (H3). Cardiac virus concentrations were equivalent in H3- and H310A1-infected mice irrespective of adriamycin treatment. BALB/c mice treated with either 0.1 ml of complete Freund's adjuvant (CFA), 10 mg of adriamycin, or 10(5) PFU of H3 and H310A1 i.p. developed cytolytic Thy 1.2+ lymphocytes (CTL) to H3-infected myocytes 7 days later. CFA-, adriamycin-, and H3-treated mice developed CTL expressing the gamma delta+ T-cell receptors, while H310A1-infected animals did not. Only H3- and H310A1-infected mice developed alpha beta+ CTL. Treatment of BALB/c mice with 0.1 ml of CFA 5 days prior to H310A1 infection dramatically increased myocarditis. Selective depletion of gamma delta+ T cells abrogated this effect. The ability of gamma delta+ T cells to augment the pathogenicity of H310A1 infection was confirmed by adoptive transfer of CFA-stimulated T cells depleted of either gamma delta- or gamma delta+ cells into H310A1-infected recipients.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1311095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1656071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1717270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1830862,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1832874,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1847455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-1915444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2106682,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2129500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2139700,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2145388,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2145390,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2188668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2387313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2435789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2459202,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2524009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2524273,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2547722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2650861,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2653373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2665772,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2848919,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-2978457,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3003209,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3320376,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3489186,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3499575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3621346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3680946,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-3753614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-445504,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-4610045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-6325164,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-6482445,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1328680-7356727
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6541-6
|
|
pubmed:dateRevised |
2010-9-7
|
|
pubmed:meshHeading |
pubmed-meshheading:1328680-Animals,
pubmed-meshheading:1328680-Animals, Newborn,
pubmed-meshheading:1328680-Cell Separation,
pubmed-meshheading:1328680-Coxsackievirus Infections,
pubmed-meshheading:1328680-Doxorubicin,
pubmed-meshheading:1328680-Enterovirus B, Human,
pubmed-meshheading:1328680-Freund's Adjuvant,
pubmed-meshheading:1328680-Heart,
pubmed-meshheading:1328680-Lymphocyte Depletion,
pubmed-meshheading:1328680-Male,
pubmed-meshheading:1328680-Mice,
pubmed-meshheading:1328680-Mice, Inbred BALB C,
pubmed-meshheading:1328680-Myocarditis,
pubmed-meshheading:1328680-Myocardium,
pubmed-meshheading:1328680-Receptors, Antigen, T-Cell, gamma-delta,
pubmed-meshheading:1328680-T-Lymphocytes,
pubmed-meshheading:1328680-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:1328680-Virulence
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
T cells expressing the gamma delta T-cell receptor potentiate coxsackievirus B3-induced myocarditis.
|
|
pubmed:affiliation |
Department of Pathology, University of Vermont, Burlington 05405-0068.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
